Abstract
The objective of this study was to evaluate the effects of angiotensin-converting enzyme (ACE) inhibitors and pharmacogenetic interaction on the survival of the patients with diastolic heart failure (DHF). A total of 285 subjects with DHF confirmed by echocardiography were recruited in the period between 1995 and 2003. Baseline characteristics (age, sex, prior history, medication, and echocardiographic findings) and genetic polymorphisms (ACE gene insertion/deletion (I/D) polymorphism; T174M, M235T, G-6A, A-20C, G-152A, and G-217A polymorphisms of the angiotensinogen (AGT) gene; and A1166C polymorphisms of the angiotensin II type I receptor (AT1R)) were collected and matched (by propensity score) in those who received and those who did not receive ACE inhibitors. The patients were followed up to 10 years. Kaplan–Meier curves and Cox regression models were used to demonstrate the survival trend. The 85 patients who received ACE inhibitors and the other 85 patients who did not were found to have comparable baseline characteristics and polymorphism distribution. Prescription of ACE inhibitors was associated with a significant decrease in overall mortality (hazard ratio (HR), 0.45; 95% confidence interval (CI), 0.24–0.83; P=0.01), and a lower rate of cardiovascular events at 4000 days (HR, 0.53; 95% CI, 0.32–0.90; P=0.02). In addition, ACE I/D gene D allele was associated with higher overall mortality as compared with the I allele (HR, 2.04; P=0.003). This effect was diminished in those who received ACE inhibitors. The use of ACE inhibitor was associated with a significant decrease in long-term mortality and cardiovascular events in the patients with DHF. Genetic variants in the renin-angiotensin system genes were also associated, but their effects could be modified by the use of ACE inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208–225.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM . Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.
Zile MR . Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003; 41: 1519–1522.
Yturralde RF, Gaasch WH . Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005; 47: 314–319.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D . Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948–1955.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2002–2007.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M . Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol 2008; 101: 639–644.
Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 2008; 94: 573–580.
European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990–1003.
Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004; 109: 1640–1646.
Wu CK, Tsai CT, Hwang JJ, Luo JL, Juang JJ, Hsu KL et al. Renin-angiotensin system gene polymorphisms and diastolic heart failure. Eur J Clin Invest 2008; 38: 789–797.
Haviland A, Nagin DS, Rosenbaum PR . Combining propensity score matching and group-based trajectory analysis in an observational study. Psychol Methods 2007; 12: 247–267.
Feinstein A . The role of observational studies in the evaluation of therapy. Stat Med 1984; 3: 341–345.
Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ et al. propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J 2007; 28: 1334–1343.
Chen YS, Lin JW, Yu HY, Ko WJ, Jerng JS, Chang WT et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008; 372: 554–561.
Philbin EF, Rocco Jr TA . Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 1997; 134: 188–195.
Philbin EF, Rocco Jr TA, Lindenmuth NW, Ulrich K, Jenkins PL . Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605–613.
Grigorian Shamagian L, Roman AV, Ramos PM, Veloso PR, Bandin Dieguez MA, Gonzalez-Juanatey JR . Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study. J Card Fail 2006; 12: 128–133.
Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.
Huang W, Xie C, Zhou H, Yang T, Sun M . Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients. Eur J Heart Fail 2004; 6: 23–27.
Schut AF, Bleumink GS, Stricker BH, Hofman A, Witteman JC, Pols HA et al. Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J 2004; 25: 2143–2148.
Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL . A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708–712.
Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, Witteman JC . Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke 2003; 34: 1634–1639.
Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A . ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484–492.
Wu CK, Tsai CT, Chang YC, Luo JL, Wang YC, Hwang JJ et al. Genetic Polymorphisms of the Angiotensin II type 1 receptor gene and diastolic heart failure. J Hyperten 2009; 27: 502–507.
Wu CK, Luo JL, Wu XM, Tsai CT, Lin JW, Hwang JJ et al. A propensity score based case control study of renin-angiotensin system gene polymorphisms and diastolic heart failure. Atherosclerosis 2009; 205: 497–502.
Flesch M, Schiffer F, Zolk O, Pinto Y, Stasch JP, Knorr A . et al. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997; 15: 1001–1009.
Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Am Heart J 1999; 137: 653–657.
Acknowledgements
We are indebted to the study coordinators who enrolled the patients from National Taiwan University Hospital and its affiliations.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Wu, CK., Luo, JL., Tsai, CT. et al. Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. Pharmacogenomics J 10, 46–53 (2010). https://doi.org/10.1038/tpj.2009.39
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2009.39
Keywords
This article is cited by
-
Development and application of low-cost T-ARMS-PCR assay for AGT and CYP11B1 gene polymorphisms
Molecular Biology Reports (2019)
-
Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices
Scientific Reports (2015)
-
Accumulation of epicardial fat rather than visceral fat is an independent risk factor for left ventricular diastolic dysfunction in patients undergoing peritoneal dialysis
Cardiovascular Diabetology (2013)
-
The Relationship Among Central Obesity, Systemic Inflammation, and Left Ventricular Diastolic Dysfunction as Determined by Structural Equation Modeling
Obesity (2012)
-
Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges
Current Heart Failure Reports (2012)